All In Biotech

Drug Trial Radar · NCT04378075

A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy

Last checked: Nov 20, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

68

Actual

Start

Sep 28, 2020

Primary completion

Mar 18, 2023

Study completion Dec 27, 2023

Sponsor

Lead sponsor
PTC TherapeuticsIndustry
Sponsor type
Industry
First posted
May 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase. After completion of the randomized, placebo-controlled phase, participants may enter a 48-week, long-term, extension phase during which they will receive open-label treatment with vatiquinone.

Conditions

  • Mitochondrial Diseases
  • Drug Resistant Epilepsy
  • Leigh Disease
  • Leigh Syndrome
  • Mitochondrial Encephalopathy (MELAS)
  • Pontocerebellar Hypoplasia Type 6 (PCH6)
  • Alpers Disease
  • Alpers Syndrome

Interventions

  • VatiquinoneDrug

    Vatiquinone will be administered per the treatment arm description.

  • PlaceboOther

    Vatiquinone-matching placebo will be administered per the treatment arm description

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures Per 28 Days During the Double-blind PeriodTime frame: Baseline to Week 24

Locations

27 sites in 9 countries. Site status is shown where the registry gives one.

  • University of California

    San Diego, California

  • Stanford University

    Stanford, California

  • Yale School of Medicine

    New Haven, Connecticut

  • Children's National Medical Center - Department Of Neurology

    Washington D.C., District of Columbia

  • John Hopkins Medicine

    Baltimore, Maryland

  • Pediatric Genetics Clinic (Main MGH Hospital)

    Boston, Massachusetts

  • Boston Children Hospital

    Boston, Massachusetts

  • Children's of Minnesota

    Minneapolis, Minnesota

  • Akron Children's Hospital

    Akron, Ohio

  • Baylor College of Medicine

    Houston, Texas

  • University of Texas Health Science

    Houston, Texas

  • Seattle Children's hospital

    Seattle, Washington

  • Alberta Children's Hospital, University of Calgary

    Calgary, Canada

  • CHU d'Angers - Service de génétique

    Angers, France

  • CHU de Montpellier - Hôpital Gui de Chauliac - Département de neuropédiatrie

    Montpellier, France

  • A.P.H.P - Hôpital Necker-Enfants Malades - Service de Neurologie pédiatrique

    Paris, France

  • CHU de Strasbourg - Hôpital de Hautepierre - Service de Neuropédiatrie

    Strasbourg, France

  • UOC Neuropsichiatria Infantile, Istituto Neurologico Carlo Besta-Fondazione IRCCS

    Milan, Italy

  • U.O.C. Malattie Muscolari e Neurodegenerative, Dipartimento di Scienze Neurologiche e Psichiatriche, Ospedale Pediatrico Bambino Gesù

    Roma, Italy

  • PTC Clinical Site

    Multiple Locations, Japan

  • Instytut Pomnik-Centrum Zdrowia Dziecka, Centrum Wsparacia Pediatrycznych Badań Klinicznych

    Warsaw, Poland

  • Hospital Sant Joan de Déu

    Barcelona, Spain

  • Hospital Ruber Internacional, Neurology Department, Epilepsy Program

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Karolinska University hospital, Astrid Lindgrens Children Hospital

    Stockholm, Sweden

  • Great Ormond Street Hospital for Children NHS Foundation Trust

    London, United Kingdom

  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.